SPR 001

Drug Profile

SPR 001

Alternative Names: SPR-001

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spruce Biosciences
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital adrenal hyperplasia
  • Research Unspecified

Most Recent Events

  • 05 Jan 2018 SPR 001 receives Orphan Drug status for Congenital adrenal hyperplasia in European Union
  • 04 Dec 2017 SPR 001 - Spruce Biosciences receives Orphan Drug status for Congenital adrenal hyperplasia in USA
  • 29 Aug 2017 Early research in Undefined indication in USA before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top